Pocared EIB Event
Pocared Diagnostics secures a EUR 22 million EIB backing for completion of the development and commercialization of its rapid testing system
POCARED Diagnostics Secures $50 Million Capital Commitment From GEM as Company envisages going public via SPAC merger
POCARED announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM")
Poster presentation: Saturday Jun 22, 2019. 11 am-12 pm and 4 pm - 5 pm.
POCARED Diagnostics Ltd. Announces Real time Identification of Bacterial Species and Antibiotic Resistance Markers
a leading in-vitro diagnostic and pre-analytical technologies manufacturer announces a breakthrough in real time identification of bacterial species and antibiotic resistance markers utilizing its proprietary technology in the P 1000.
Introducing the first system that can perform both direct, automated Gram staining and sample concentration.
The company raised an additional $15 million (milestone-based) in funding to complete its clinical trials and increase manufacturing capacity while preparing to commercialize both the POCARED P-1000TM and SP platforms.
Mr. Ludwig is former Chairman of the Board, President and Chief Executive Officer of BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company headquartered in Franklin Lakes, New Jersey.